Clinical Trial Update: A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Tirzepatide (LY3298176) to Insulin Degludec in adults with Type 2 Diabetes; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tirzepatide (tirzepatide)
• insulin degludec (insulin degludec)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2022-01-19